What is it about?
KCa channels are involved in inflammation. Treatment with a KCa blocker may be a method of treating inflammation in the ocular surface. We synthesize a nanoliposomal formulation of the KCa blocker, so that sustained release do not require frequent instillation of the medication, thus allowing for greater patient compliance.
Featured Image
Photo by Markus Winkler on Unsplash
Why is it important?
Ocular surface inflammation affects many common diseases such as dry eye, ocular allergies, infections and many other conditions.
Perspectives
Ion channel therapeutics may play a role in treatment of dry eye
Prof Louis Tong
National University of Singapore
Read the Original
This page is a summary of: Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments, International Journal of Molecular Sciences, September 2018, MDPI AG,
DOI: 10.3390/ijms19102977.
You can read the full text:
Contributors
The following have contributed to this page
